Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate- channel interactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 2, 2009, Pages 563-573

  Ponce Balbuena, Daniela ^a   López Izquierdo, Angélica ^a   Ferrer, Tania ^a   Rodríguez Menchaca, Aldo A ^a   Aréchiga Figueroa, Iván A ^a   Sánchez Chapula, José A ^a  

^a UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.2; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.3; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; RALOXIFENE; SPERMINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CHANNEL GATING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ELECTRIC POTENTIAL; EMBRYO; HEART LEFT ATRIUM; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; POINT MUTATION; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REACTION TIME;

ANIMALS; CATS; CELL LINE; CHLOROQUINE; ELECTROPHYSIOLOGY; ESTROGEN ANTAGONISTS; HEART ATRIA; HEART VENTRICLES; HUMANS; ION CHANNEL GATING; ION CHANNELS; KINETICS; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHOSPHATIDYLINOSITOL 4,5-DIPHOSPHATE; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RALOXIFENE; TAMOXIFEN; TRANSFECTION;

EID: 70350452581     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156075     Document Type: Article

References (39)

1. Allan D and Michell RH (1975) Enhanced synthesis de novo of phosphatidylinositol in lymphocytes treated with cationic amphiphilic drugs. Biochem J 148:471-478.
2. Allen MC, Newland C, Valverde MA, and Hardy SP (1998) Inhibition of ligand-gated cation-selective channels by tamoxifen. Eur J Pharmacol 354:261-269. (Pubitemid 28401460)
3. Andersen OS and Koeppe RE, 2nd (2007) Bilayer thickness and membrane protein function: an energetic perspective. Annu Rev Biophys Biomol Struct 36:107-130. (Pubitemid 46998112)
4. Berman E, McBride M, Lin S, Menedez-Botet C, and Tong W (1995) Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9:1631-1637.
5. Conrad MJ and Singer SJ (1981) The solubility of amphipathic molecules in biological membranes and lipid bilayers and its implications for membrane structure. Biochemistry 20:808-818.
6. Custódio JB, Almeida LM, and Madeira VM (1993a) The active metabolite hydroxytamoxifen of the anticancer drug tamoxifen induces structural changes in membranes. Biochim Biophys Acta 1153:308-314. (Pubitemid 24028303)
7. Custódio JB, Almeida LM, and Madeira VM (1993b) The anticancer drug tamoxifen induces changes in the physical properties of model and native membranes. Biochim Biophys Acta 1150:123-129. (Pubitemid 23246702)
8. Dhamoon AS, Pandit SV, Sarmast F, Parisian KR, Guha P, Li Y, Bagwe S, Taffet SM, and Anumonwo JM (2004) Unique Kir2.x properties determine regional and species differences in the cardiac inward rectifier K+ current. Circ Res 94:1332-1339. (Pubitemid 38724479)
9. Du X, Zhang H, Lopes C, Mirshahi T, Rohacs T, and Logothetis DE (2004) Characteristic interactions with phosphatidylinositol 4,5-bisphosphate determine regulation of Kir channels by diverse modulators. J Biol Chem 279:37271-37281. (Pubitemid 39195433)
10. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71-85.
11. Ehrlich JR (2008) Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol 52:129-135.
12. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388. (Pubitemid 28439961)
13. Franks NP (2006) Molecular targets underlying general anaesthesia. Br J Pharmacol 147 (Suppl 1):S72-S81.
14. Friedman ZY (1993) Tamoxifen and vanadate synergize in causing accumulation of polyphosphoinositides in GH4C1 membranes. J Pharmacol Exp Ther 267:617-623.
15. Grzeda KR, Anumonwo JM, O'Connell R, and Jalife J (2009) A single-cell model of phase-driven control of ventricular fibrillation frequency. Biophys J 96:2961-2976.
16. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391:85-100. (Pubitemid 11012976)
17. Hardy SP, deFelipe C, and Valverde MA (1998) Inhibition of voltage-gated cationic channels in rat embryonic hypothalamic neurones and C1300 neuroblastoma cells by triphenylethylene antioestrogens. FEBS Lett 434:236-240.
18. + currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 285:H661-H668.
19. Huang CL, Feng S, and Hilgemann DW (1998) Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature 391:803-806. (Pubitemid 28099680)
20. Jordan VC (1984) Biochemical pharmacology of antiestrogen action. Pharmacol Rev 36:245-276.
21. Liu XK, Katchman A, Ebert SN, and Woosley RL (1998) The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287:877-883. (Pubitemid 29131595)
22. Logothetis DE, Jin T, Lupyan D, and Rosenhouse-Dantsker A (2007) Phosphoinositide-mediated gating of inwardly rectifying K(+) channels. Pflugers Arch 455:83-95. (Pubitemid 47403981)
23. Lundbaek JA (2008) Lipid bilayer-mediated regulation of ion channel function by amphiphilic drugs. J Gen Physiol 131:421-429.
24. McDonald CC and Stewart HJ (1991) Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ 303:435-437.
25. Melnyk P, Zhang L, Shrier A, and Nattel S (2002) Differential distribution of Kir2.1 and Kir2.3 subunits in canine atrium and ventricle. Am J Physiol Heart Circ Physiol 283:H1123-H1133. (Pubitemid 34941050)
26. Murphy C, Fotsis T, Pantzar P, Adlercreutz H, and Martin F (1987) Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). J Steroid Biochem 26:547-555. (Pubitemid 17066987)
27. + current (I K1) in the mouse heart accelerates and stabilizes rotors. J Physiol 578:315-326.
28. Pegan S, Arrabit C, Zhou W, Kwiatkowski W, Collins A, Slesinger PA, and Choe S (2005) Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci 8:279-287. (Pubitemid 40300184)
29. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, et al. (1997) A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3:1109-1115. (Pubitemid 27319757)
30. Rodríguez-Menchaca AA, Navarro-Polanco RA, Ferrer-Villada T, Rupp J, Sachse FB, Tristani-Firouzi M, and Sánchez-Chapula JA (2008) The molecular basis of chloroquine block of the inward rectifier Kir2.1 channel. Proc Natl Acad Sci U S A 105:1364-1368.
31. Sánchez-Chapula JA, Salinas-Stefanon E, Torres-Jácome J, Benavides-Haro DE, and Navarro-Polanco RA (2001) Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther 297:437-445. (Pubitemid 32242605)
32. Song J, Standley PR, Zhang F, Joshi D, Gappy S, Sowers JR, and Ram JL (1996) Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 277:1444-1453. (Pubitemid 27167158)
33. Suh BC and Hille B (2005) Regulation of ion channels by phosphatidylinositol 4,5-bisphosphate. Curr Opin Neurobiol 15:370-378. (Pubitemid 40806451)
34. Verrecchia F and Hervé JC (1997) Reversible inhibition of gap junctional communication elicited by several classes of lipophilic compounds in cultured rat cardiomyocytes. Can J Cardiol 13:1093-1100. (Pubitemid 28004551)
35. Wang Z, Yue L, White M, Pelletier G, and Nattel S (1998) Differential distribution of inward rectifier potassium channel transcripts in human atrium versus ventricle. Circulation 98:2422-2428. (Pubitemid 28549786)
36. Warren M, Guha PK, Berenfeld O, Zaitsev A, Anumonwo JM, Dhamoon AS, Bagwe S, Taffet SM, and Jalife J (2003) Blockade of the inward rectifying potassium current terminates ventricular fibrillation in the guinea pig heart. J Cardiovasc Electrophysiol 14:621-631. (Pubitemid 36733543)
37. + channels. Nat Neurosci 6:811-818.
38. Xie LH, John SA, Ribalet B, and Weiss JN (2005) Long polyamines act as cofactors in PIP2 activation of inward rectifier potassium (Kir2.1) channels. J Gen Physiol 126:541-549. (Pubitemid 41713735)
39. Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepúlveda FV, Gill DR, Hyde SC, Trezise AE, and Higgins CF (1994) Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 94:1690-1697. (Pubitemid 24309895)